View Item 

Show simple item record

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

dc.contributor.authorTaylor, Sarah A.en_US
dc.contributor.authorFleming, Thomas R.en_US
dc.contributor.authorHoff, Daniel D.en_US
dc.contributor.authorMcCracken, Joseph D.en_US
dc.contributor.authorBukowski, Ronald M.en_US
dc.contributor.authorTalley, Robert W.en_US
dc.contributor.authorNatale, Robert B.en_US
dc.contributor.authorGuy, Jerry T.en_US
dc.contributor.authorSamlowski, Wolfram E.en_US
dc.contributor.authorCostanzi, John H.en_US
dc.date.accessioned2006-09-11T15:55:26Z
dc.date.available2006-09-11T15:55:26Z
dc.date.issued1990-02en_US
dc.identifier.citationTaylor, Sarah A.; Fleming, Thomas; Hoff, Daniel D.; McCracken, Joseph D.; Bukowski, Ronald M.; Talley, Robert W.; Natale, Robert B.; Guy, J. T.; Samlowski, Wolfram E.; Costanzi, John H.; (1990). "Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study." Investigational New Drugs 8(1): 77-80. <http://hdl.handle.net/2027.42/45319>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45319
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2188928&dopt=citationen_US
dc.description.abstractPatient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin ⩽ 1.5 mg% received mitoxantrone 12 mg/m 2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.en_US
dc.format.extent247880 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherMitoxantroneen_US
dc.subject.otherPancreatic Carcinomaen_US
dc.subject.otherPhase II Trialen_US
dc.subject.otherDHADen_US
dc.subject.otherNovantroneen_US
dc.titlePhase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, USAen_US
dc.contributor.affiliationotherUniversity of Kansas Medical Center, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Group Biostatistical Center, Seattleen_US
dc.contributor.affiliationotherUniversity Texas Health Science Center, San Antonioen_US
dc.contributor.affiliationotherBrooke Army Medical Center, USAen_US
dc.contributor.affiliationotherCleveland Clinic Foundation, USAen_US
dc.contributor.affiliationotherHenry Ford Hospital, USAen_US
dc.contributor.affiliationotherOhio State University Hospital, USAen_US
dc.contributor.affiliationotherUniversity of Utah Medical Center, USAen_US
dc.contributor.affiliationotherUniversity of Texas, Galveston, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2188928en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45319/1/10637_2004_Article_BF00216928.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00216928en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00216928.pdf
Size:
242.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.